Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14QXP | ISIN: FR0012127173 | Ticker-Symbol: 6OP
Tradegate
26.06.25 | 10:09
5,210 Euro
+2,26 % +0,115
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OSE IMMUNOTHERAPEUTICS SA Chart 1 Jahr
5-Tage-Chart
OSE IMMUNOTHERAPEUTICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,0655,18528.06.
5,0705,11527.06.

Aktuelle News zur OSE IMMUNOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiOSE Immunotherapeutics provides an update on ongoing proceedings81OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25th, 2025, 8:00 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing...
► Artikel lesen
20.06.OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules81OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules Nantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN:...
► Artikel lesen
11.06.OSE Immunotherapeutics: ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 202510
05.06.OSE Immunotherapeutics - New UC biomarker underpins growth strategy325OSE has announced plans to strengthen its growth strategy and accelerate the key pillars of its pipeline, covering immuno-inflammation and immuno-oncology. In the inflammation space, the company revealed...
► Artikel lesen
04.06.Ose Immunotherapeutics: Documents made available to the shareholders for the combined general meeting of June 25th, 20253
OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln
04.06.OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology210OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab...
► Artikel lesen
03.06.OSE Immunotherapeutics - ASCO 2025 update showcases Tedopi potential276OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to Tedopi, its proprietary off-the-shelf neoepitope-based cancer...
► Artikel lesen
02.06.OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi in Pancreatic Cancer and Non-Small Cell Lung Cancer291OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer Two presentations at the American Society of Clinical...
► Artikel lesen
23.05.OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials at ASCO 2025257OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials...
► Artikel lesen
22.05.OSE Immunotherapeutics - Strategic collaboration in mRNA technologies311OSE Immunotherapeutics has announced a new strategic collaboration with Inside Therapeutics and MiNT Laboratory (University of Angers) to develop mRNA therapies and accelerate nanodrug development....
► Artikel lesen
21.05.France invests €1.3M into novel mRNA project led by OSE Immunotherapeutics2
21.05.OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies355OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies OSE Immunotherapeutics to lead French consortium with Inside Therapeutics and MiNT Laboratory (University...
► Artikel lesen
06.05.OSE Immunotherapeutics - Lusvertikimab impresses in extension period data313OSE Immunotherapeutics has presented new data for lusvertikimab in ulcerative colitis (UC), with encouraging results from the extension period of the Phase II CoTikiS trial. The key takeaway was that...
► Artikel lesen
05.05.OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab80OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period.Oral...
► Artikel lesen
30.04.OSE Immunotherapeutics: Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025295Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response...
► Artikel lesen
23.04.OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 20251
09.04.OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 20252
03.04.OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 20252
03.04.OSE Immunotherapeutics - Primed for value appreciation372OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The company recently reported its FY24 results, reflecting...
► Artikel lesen
26.03.OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update99OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million1 as of December 31, 2024, ensuring financial...
► Artikel lesen
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1